We use cookies to make this site work. We'd also like to set optional cookies so we can understand how the site is used and improve it. We will not set optional cookies unless you accept them. You can change your choice at any time from the Cookie settings link in the footer.
Strictly necessary cookies
These cookies are required for the site to work. They store your cookie preferences and keep your session secure. They are exempt from consent under PECR Regulation 6(4) because they are essential to deliver the service you have requested.
Optional cookies
Optional cookies help us understand how the site is used and provide additional features such as analytics, accessibility tools and translation. We will only set them if you accept.
Mounjaro (Tirzepatide)
Information regarding the availability of weight-loss injections on the NHS
Tirzepatide, for the treatment of overweight and obesity is the first pharmacotherapy to be approved by NICE to be made available from a primary care setting and will be made available from the 1st July.
Cohort 1
Year 1 (2025-2026) - Duration 12 months
Comorbidities
At least 4 out of the 5 following conditions:
- Hypertension,
- Dyslipidaemia,
- Obstructive sleep apnoea,
- Cardiovascular disease,
- 5. Type 2 diabetes mellitus
BMI
With a BMI of 40kg/m2 or above (or 37.5kg/m2 for people from a South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean ethnic background).
- We have identified the patients who are eligible for the NHS weight loss management service, and we will be contacting them directly to discuss further
- If you do not meet the above criteria, we will not be able to prescribe weight loss injections.
Published: Jun 25, 2025
Providing NHS Services
Pound House Surgery
8 The Green
Wooburn Green
Buckinghamshire
HP10 0EE
Telephone: 01628 530 997
Hawthornden Surgery
Wharf Lane
Bourne End
Buckinghamshire
SL8 5RX
Telephone: 01628 530 997
The Orchard Surgery
Station Road
Bourne End
Buckinghamshire
SL8 5QE
Telephone: 01628 530 997